Jenny Seligmann: Liver Mets in MSS Metastatic Colorectal Cancer Remain a Huge Unmet Need
Jenny Seligmann, Professor of Gastrointestinal Oncology at the University of Leeds, shared a post on LinkedIn about recent paper he and colleagues co-authored, published in ESMO Open.
“Liver mets in MSS metastatic colorectal cancer remain huge unmet need…
EORTC 1560 was a phase 2 trial testing whether immunotherapy plus ablation would lead to responses through an abscopal effect. Unfortunately no responses seen in 21 patients and study closed due to futility.
More effective strategies are needed for this population! Thanks to the patients, investigators and EORTC.”
Title: Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
Authors: J. Seligmann, T. Koessler, M. Mauer, S. Evrard, J. Freedman, E.C. Gootjes, M. Guckenberger, A.S. Govaerts, A. Giraut, J. Ricke, G. Folprecht, D. Arnold, P. Giasafaki, M. Ducreux, S. Antunes, T. Ruers
Read The Full Article at ESMO Open.
More posts featuring Jenny Seligmann.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023